Intellia Therapeutics Inc (NTLA) concluded trading on Thursday at a closing price of $10.86, with 3.75 million shares of worth about $40.75 million changed hands on the day. Half year performance of the stock remained negative as price took a plunge of -53.94% during that period and on February 27, 2025 the price saw a gain of about 0.56%. Currently the company’s common shares owned by public are about 101.80M shares, out of which, 96.20M shares are available for trading.
Stock saw a price change of -11.35% in past 5 days and over the past one month there was a price change of 8.49%. Year-to-date (YTD), NTLA shares are showing a performance of -6.86% which decreased to -60.74% when we look at its performance for past 12 months. Over the period of past 52 weeks, stock dropped to lowest price of $8.96 but also hit the highest price of $34.87 during that period. The average intraday trading volume for Intellia Therapeutics Inc shares is 2.87 million. The stock is currently trading 2.86% above its 20-day simple moving average (SMA20), while that difference is down -1.69% for SMA50 and it goes to -41.37% lower than SMA200.
Intellia Therapeutics Inc (NASDAQ: NTLA) currently have 101.80M outstanding shares and institutions hold larger chunk of about 91.78% of that.
The stock has a current market capitalization of $1.11B and its 3Y-monthly beta is at 1.96. It has posted earnings per share of -$5.45 in the same period. It has Quick Ratio of 6.73 while making debt-to-equity ratio of 0.11. Volatility of a stock is a metric used to know how much the price of that stock is under influence and for NTLA, volatility over the week remained 8.61% while standing at 7.33% over the month.
Stock’s fiscal year EPS is expected to rise by 6.96% while it is estimated to increase by 2.81% in next year. EPS is likely to grow at an annualized rate of 32.98% for next 5-years, compared to annual growth of -22.30% made by the stock over the past 5-years.
Digging deeper we find that several firms have released their research notes about the support levels of the stock. Most recent of them is a note released by Morgan Stanley on January 27, 2025 offering an Equal-weight rating for the stock and assigned a target price range of between $56 and $11 to it. Coverage by Goldman stated Intellia Therapeutics Inc (NTLA) stock as a Neutral in their note to investors on February 23, 2024, suggesting a price target of $32 for the stock. On February 15, 2024, Wolfe Research Initiated their recommendations, while on April 13, 2023, Canaccord Genuity Initiated their ratings for the stock with a price target of $66. Stock get an Outperform rating from Bernstein on March 21, 2023.
